Product/Composition:- | Ambroxol tablet |
---|---|
Strength:- | 30 mg, 60 mg, or 75 mg |
Form:- | Tablet |
Reference Brands:- | Mucosolvan(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ambroxol tablets work by stimulating mucus production and enhancing ciliary function, promoting the clearance of thick mucus from airways. They also have anti-inflammatory properties. Benefits include improved airway clearance, reduced cough, and relief from respiratory conditions like bronchitis and COPD, helping to improve breathing and overall respiratory health.
Ambroxol tablets are approved in the EU and other regions, with regulatory oversight from agencies like the EMA. In the US, Ambroxol is not officially approved but is available in some markets globally. Regulatory dossiers include comprehensive safety, efficacy, and manufacturing data aligned with GMP standards. In Europe, products like Mucosolvan are well-established, supported by approved dossiers demonstrating quality and performance. For detailed information on regulatory submissions, approved dossiers, and licensing workflows for Ambroxol tablets, visit Pharmatradz. Stay informed on the latest regulatory updates and licensing requirements for Ambroxol across different markets.